Trial
NCT04169360
Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Opioid-use Disorder
Intervention
ANS-6637
Why stopped
The FDA determined that there is not adequate safety information to continue clinical investigations using ANS-6637 and Amygdala Neurosciences, the product company of ANS-6637, is no longer pursuing research with this compound.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-28